Last reviewed · How we verify
MGd
MGd is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells to reduce proliferation and survival of malignant cells.
MGd is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells to reduce proliferation and survival of malignant cells. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL).
At a glance
| Generic name | MGd |
|---|---|
| Also known as | MGd plus WBRT |
| Sponsor | Pharmacyclics LLC. |
| Drug class | Bruton's tyrosine kinase (BTK) inhibitor |
| Target | BTK (Bruton's tyrosine kinase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
MGd irreversibly binds to BTK, a key enzyme in B-cell receptor signaling, preventing downstream activation of survival and proliferation pathways. This mechanism is particularly effective in B-cell malignancies where BTK signaling is critical for tumor cell survival. The drug has demonstrated clinical activity in chronic lymphocytic leukemia and other lymphoid malignancies.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Infection
- Hemorrhage
Key clinical trials
- Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD (NA)
- Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (PHASE4)
- A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)
- Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction (NA)
- A Prospective, Randomized, Controlled Trial of the TearCare MGX™ System With and Without Warming Hold (NA)
- Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy
- Treating Meibomian Gland Disease in a Pediatric Population (NA)
- Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MGd CI brief — competitive landscape report
- MGd updates RSS · CI watch RSS
- Pharmacyclics LLC. portfolio CI